AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Integra LifeSciences Holdings Corporation
Video analysis: IART
All videosNo video analysis for this stock yet. Request one from our team.
News: IART
Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, and Michael McBreen, chief commercial officer, will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 2:15 p.m. ET. Stuart Essig, chairman and chief executive officer, will present at the 2026 Morgan Stanley Healthcare Conference on Tuesday, September 15, 2026, at 4:05 p.m. ET.
Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis
Integra LifeSciences Holdings is a turnaround story, maintaining a BUY rating after a strong 2Q26 earnings beat and margin expansion. IART's specialty surgery segment led revenue, while tissue reconstruction saw declines offset by a successful PriMatrix relaunch and upcoming SurgiMend reintroduction. Management targets leverage reduction to 2.5–3.5x by end-2026, prioritizing debt repayment as operating cash flow improves.
Integra (IART) Down 1.6% Since Last Earnings Report: Can It Rebound?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
Why Integra LifeSciences (IART) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?
Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.
Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript
